VIDEO: ‘Good research’ at lung cancer conference ‘answers some questions,’ creates others
Click Here to Manage Email Alerts
In this video, Hossein Borghaei, DO, MS, discusses safety, response and survival data of patients with small cell lung cancer who received tarlatamab, a half-life extended bispecific T-cell engager, or HLE BiTE.
The phase one dose expansion findings were presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
“Overall, it’s an interesting response rate and durability of responses,” Borghaei, co-author of the study and chief of thoracic medical oncology, professor of hematology/oncology, co-director of the Immune Monitoring Facility and the Gloria and Edmund M. Dunn Chair in Thoracic Oncology at Fox Chase Cancer Center, said. “The hope is we can continue identifying the patients who would necessarily benefit from this and also try to see if there is a potential of bringing this agent a little bit earlier in the line of treatment as opposed to second-, third-line type of a setting.”
He also highlighted updates in the KRAS targeted treatment area, including data on sotorasib (Lumakras, Amgen) and combination therapy. According to Borghaei, treatment research in the KRAS G12C space is focused on determining whether the different agents are “that different from one another.”
“That’s what any good research does,” he said. “It answers some questions and opens up the door for a few more.”
References:
- Borghaei H, et al. Abstract OA12.05. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
- Johnson ML. Abstract EP08.02-111. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
- Li BT, et al. Abstract OA03.06. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Collapse
Healio Interviews
Click Here to Manage Email Alerts